ANI Pharmaceuticals Announces Offer At SEK 11.25 Per Share, About SEK 5.6B ($560M), To Acquire Egetis Therapeutics, Expanding Rare Disease Business
Egetis Therapeutics’ lead asset, EMCITATE®, is the first and only approved treatment in U.S. and Europe for peripheral thyrotoxicosis associated with MCT8 deficiency, a rare genetic disorder, impacting approximately 1
ANI Pharmaceuticals is buying a company that makes a rare disease medicine. This shows ANI wants to grow in treating unusual genetic disorders that few people have.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.